Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study.
Aliment Pharmacol TherJul 1, 2026 (epub)
Clinical ResearchGastroenterology
Omesh Goyal, Manjeet Kumar Goyal, Bhupinder Singh et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, pragmatic clinical trial compared the efficacy of elobixibat and prucalopride in treating functional constipation (FC) in adults. Among 214 patients, elobixibat achieved a significantly higher sustained complete spontaneous bowel movement (CSBM) response of 55.6% compared to 33.9% for prucalopride (p = 0.024), indicating its superior effectiveness.
Key findings
- Elobixibat achieved a sustained CSBM response of 55.6% compared to 33.9% for prucalopride (p = 0.024).
- Elobixibat showed greater improvement in straining (p < 0.001) and abdominal discomfort (p = 0.005).
- Quality of life improved significantly with elobixibat (p = 0.009) compared to prucalopride.
Why it matters
The study highlights the importance of direct comparisons between treatments for functional constipation, providing evidence that elobixibat may offer superior symptomatic relief and quality of life improvements, which can guide treatment decisions.